Karidox 10% Oral Solution

Main information

  • Trade name:
  • Karidox 10% Oral Solution
  • Pharmaceutical form:
  • Oral solution
  • Medicine domain:
  • Animals
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • Karidox 10% Oral Solution
    United Kingdom
  • Language:
  • English

Therapeutic information

  • Therapeutic group:
  • doxycycline
  • Therapeutic area:
  • Chicken Broilers, Pigs

Other information

Status

  • Source:
  • HMA - Europe
  • Authorization number:
  • UK/V/0250/001
  • Authorization date:
  • 26-03-2008
  • EU code:
  • UK/V/0250/001
  • Last update:
  • 09-08-2016

Summary of Product characteristics: dosage,interactions,side effects

Revised:May2013

AN:00844/2012

Page1of7

SUMMARYOFPRODUCTCHARACTERISTICS

1. NAMEOFTHEVETERINARYMEDICINALPRODUCT

KARIDOX100mg/mloralsolutionforuseindrinkingwaterforchickens

andpigs[UK,ES,IT,NL,DK,RO]

DOXYSOL10%[FR]

2. QUALITATIVEANDQUANTITATIVECOMPOSITION

Compositionperml:

Doxycycline......................................................100mg

(equivalenttoDoxycyclinehyclate116.0mg)

Forafulllistofexcipients,seesection6.1

3. PHARMACEUTICALFORM

Oralsolutionforuseindrinkingwater.

Clear,dense,brownish-yellowsolution.

4. CLINICALPARTICULARS

4.1.Targetspecies

Chicken(broilers)andpigs.

4.2. Indicationsforuse,specifyingthetargetspecies

CHICKENS(BROILERS)

Preventionandtreatmentofchronicrespiratorydisease(CRD)and

mycoplasmosiscausedbymicroorganismssensitivetodoxycycline.

PIGS

PreventionofclinicalrespiratorydiseaseduetoPasteurellamultocida

andMycoplasmahyopneumoniaesensitivetodoxycycline.

Thepresenceofthediseaseintheherdshouldbeestablishedbefore

treatment.

Revised:May2013

AN:00844/2012

Page2of7

4.3.Contraindications

Donotuseincaseofhypersensitivitytotetracyclines.

Donotuseincaseofresistancetotetracyclinesoccurs.

Donotuseinanimalswithhepaticdysfunction.

4.4. Specialwarningsforeachtargetspecies

Sickanimalsmayhaveareducedappetiteandaltereddrinkingpatterns

andshould,ifnecessary,bemedicatedparenterally.

Incasesofalteredfoodordrinkingwateruptake,theconcentrations

shouldbeadjustedinsuchawaythattherecommendeddosageis

achieved.

Donotadministertolayinghens.

4.5. Specialprecautionsforuse

Specialprecautionsforuseinanimals

Prolongedorrepeateduseofthisveterinarymedicinalproductis

discouraged.Attentionshouldbepaidtoavoidanceofstressful

conditionsandimprovementofmanagementpracticesandhygiene

standards.

Avoidadministrationinoxidiseddrinkingequipment.

Useoftheproductshouldbebasedonsusceptibilitytestingofthe

bacteriaisolatedfromtheanimal.Ifthisisnotpossible,therapyshould

bebasedonlocal(regionalandfarmlevel)epidemiologicalinformation

aboutsusceptibilityofthetargetbacteria,takingintoaccountofficial

nationalantimicrobialpolicies.Inappropriateuseoftheproductmay

increasetheprevalenceofbacteriaresistanttodoxycyclineandmay

decreasetheeffectivenessoftreatmentwithtetracyclines,duetothe

potentialforcross-resistance.

Duetovariability(time,geographical)insusceptibilityofbacteriafor

doxycycline,bacteriologicalsamplingandsusceptibilitytestingofmicro-

organismsfromdiseasedbirdsonfarmarehighlyrecommended.

AhighresistancerateofE.coli,isolatedfromchickens,against

tetracyclineshasbeendocumented.Thereforetheproductshouldbe

usedforthetreatmentofinfectionscausedbyE.colionlyafter

susceptibilitytestinghasbeencarriedout.

Aseradicationofthetargetpathogensmaynotbeachieved,medication

shouldthereforebecombinedwithgoodmanagementpractices,e.g.

goodhygiene,properventilation,nooverstocking.

Specialprecautionstobetakenbythepersonadministeringthe

veterinarymedicinalproducttoanimals

Revised:May2013

AN:00844/2012

Page3of7

Tetracyclinesmay –inveryrarecases–inducephotosensitivityand

allergicreactions.

Donothandletheproductifyouarehypersensitivetotetracyclines.

Weargloves,workoverallandapprovedsafetyglasses.

Thisproductisacidandlikelytobeirritant.Avoidcontactwithskinand

eyes.Incaseofcontactwithskin,rinseimmediatelywithplentyofwater.

Incaseofcontactwitheyes,rinseimmediatelywithcopiousamountsof

waterandseekmedicaladvice.

Donotsmoke,eatordrinkwhilehandlingthisproduct.

Theproductcanbeharmfulbyskincontactandinhalationandmay

causeeyeirritation.

Incaseofaccidentalingestionseekmedicaladviseandshowthelabelto

thedoctor.

Ifanysymptomshouldappear,suchasacutaneouseruption,seek

promptmedicaladvice.Swellingoftheface,lipsoreyesorrespiratory

difficultiesarethemostserioussignswhichrequireurgentmedical

attention.

4.6. Adversereactions(frequencyandseriousness)

Allergicandphotosensitivityreactionscanoccur.Intestinalfloramaybe

affectediftreatmentisveryprolonged,andthismayresultindigestive

disturbance.

Ifsuspectedadversereactionsoccur,treatmentshouldbediscontinued.

4.7. Useduringpregnancy,lactationorlay

Theproductshouldnotbeusedduringpregnancyorlactation

4.8.Interactionwithothermedicinalproductsandotherformsof

interaction

Doxycyclineabsorptionmaybereducedbythepresenceofhigh

quantitiesofcalcium,iron,magnesiumoraluminiuminthediet.Donot

administertogetherwithantacids,kaolinandironpreparations.

Donotadministertogetherwithbactericidalantibiotics.

ThesolubilityoftheproductispHdependentandwillprecipitateifmixed

inalkalinesolution

Donotadministerwithmilkreplacers

4.9. Amountstobeadministeredandadministrationroute

Tobeadministeredindrinkingwater

- CHICKEN(broilers):11.5 –23mgdoxycyclinehyclate/kgbodyweight/

day,correspondingto0.1 –0.2mloftheveterinaryproductperkgbody

weight,for3-5consecutivedays

- PIGS:11.5mgdoxycyclinehyclate/kgbodyweight/day,corresponding

to0.1mloftheveterinaryproductperkgbodyweight,for5consecutive

days).

Revised:May2013

AN:00844/2012

Page4of7

Basedontherecommendeddose,andthenumberandweightofthe

animalstobetreated,theexactdailyamountoftheveterinaryproduct

shouldbecalculatedaccordingtothefollowingformula:

Xmlveterinary

product/kg

b.w./day

x Meanbody

weight(kg)of

animalstobe

treated

= Xml

veterinary

productperl

drinkingwater

Meandailywaterconsumption(l)peranimal

Toensureacorrectdosagebodyweightshouldbedeterminedas

accuratelyaspossibletoavoidunderdosing.Theuptakeofmedicated

waterisdependantontheclinicalconditionoftheanimals.Inorderto

obtainthecorrectdosage,theconcentrationindrinkingwatermayhave

tobeadjusted.

Theuseofsuitablycalibratedweighingequipmentisrecommendedif

partpacksareused.Thedailyamountistobeaddedtothedrinking

watersuchthatallmedicationwillbeconsumedin24hours.Medicated

drinkingwatershouldbefreshlypreparedevery24hours.Itis

recommendedtoprepareaconcentratedpre-solution –approximately

100gramsproductperlitredrinkingwater –andtodilutethisfurtherto

therapeuticconcentrationsifrequired.Alternatively,theconcentrated

solutioncanbeusedinaproportionalwatermedicator.

Medicatedwatershouldbetheonlydrinkingsource.

Theremainingmedicatedwatershouldbedisposedofinaccordance

withlocalrequirements.

Ifnoimprovementinclinicalsignsisseenwithinthetreatmentduration,

thediagnosisshouldbereviewedandtreatmentchanged.

4.10.Overdose(symptoms,emergencyprocedures,antidotes)

Nodataavailable.

4.11.Withdrawalperiod

Meat&offal:

Chickens(broilers):7days

Pigs:7days.

Eggs:Notpermittedforuseinlayingbirdsproducingeggsforhuman

consumption

5. PHARMACOLOGICALPROPERTIES

Pharmacotherapeuticgroup:Antibiotic,Tetracyclines

ATCvetcode:QJ01AA02

Revised:May2013

AN:00844/2012

Page5of7

5.1. Pharmacodynamicproperties

Doxycyclineisabacteriostaticagentthatactsbyinterferingwiththe

bacterialproteinsyntesisofsensitivespecies.

Doxycyclineisasemi-synthetictetracyclinederivedfromoxytetracicline.

Itactsonthesubunit30Softhebacterialribosome,towhichislinked

reversibly,blockingtheunionbetweenaminoacyl-tRNA(transferRNA)to

themRNA-ribosomecomplex,preventingtheadditionofnewaminoacids

intothegrowingpeptidechainandthusinterferingwithproteinsynthesis.

DoxycyclineisactiveagainstGram-positiveandGram-negativebacteria.

Spectrumofactivity:

Streptococcusspp.

Staphylococcusaureus

Chlamydiaspp.

Mycoplasmaspp.

Salmonellaspp.

Pasteurellamultocida

InvitrosensitivityofdoxycyclineagainstPasteurellamultocidaand

Bordetellabronchisepticastrainsisolatedfrompigshasbeendetermined

bymeansofaplatediffusionmethod,andagainstMycoplasma

hyopneumoniaebyadilutionmethod,withMIC

valuesof0.517

g/ml,

0.053

g/mland0.200

g/ml,respectively.

AccordingtotheNCCLSstandard,strainssensitivetodoxycyclinehave

MICvaluesbeloworequalto4

g/mlandthoseresistanthaveMIC

valuesaboveorequalto16

g/ml.

Thereareatleasttwomechanismsofresistancetotetracyclines.The

mostimportantmechanismisduetodecreasedcellularaccumulationof

thedrug.Thisisduetotheestablishmentofeitherapumpelimination

pathoranalterationinthetransportsystemthatlimitstheuptakeof

tetracycline.Thealterationinthetransportsystemisproducedby

inducibleproteinscodifiedinplasmidsandtransposons.Theother

mechanismisevidencedbydecreasedribosomeaffinitiyforthe

Tetracycline-Mg 2+

complex owing to chromosomal mutations.

Resistancetotetracyclinesmaynotonlybetheresultoftherapywith

tetracyclines,butmayalsobecausedbytherapywithotherantibiotics

leadingtoselectionofmulti-resistantstrainsincludingtetracyclines.

Althoughminimalinhibitoryconcentrations(MIC)tendtobelowerfor

doxycyclinethanforoldergenerationtetracyclines,pathogensresistant

toonetetracyclinearegenerallyalsoresistanttodoxycycline(cross

resistance).Bothlongtermtreatmentandtreatingforaninsufficient

lengthoftimeand/orsub-therapeuticdosagescanselectfor

antimicrobialresistanceandshouldbeavoided.

Revised:May2013

AN:00844/2012

Page6of7

5.2. Pharmacokineticparticulars

Doxycyclineisbioavailableafteroraladministration.Whenorally

administered,itreachesvaluesgreaterthan70%inmostspecies.

Feedingcanmodifytheoralbioavailabilityofdoxycycline.Infasting

conditionsbioavailabilityisaround10-15%greaterthanwhentheanimal

isfed.

Doxycyclineiswelldistributedthroughthebodyasitishighlylipid

soluble.Itaccumulatedinliver,kidney,bonesandintestine;

enterohepaticrecyclingoccurs.Inlungs,italwaysreacheshigher

concentrationsthaninplasma.Therapeuticconcentrationshavebeen

detectedinaqueoushumour,myocardium,reproductivetissues,brain

andmammarygland.Plasmaproteinbindingis90-92%.

40%ofthedrugismetabolizedandlargelyexcretedthroughfaeces

(biliaryandintestinalroute),mainlyasmicrobiologicallyinactive

conjugates.

CHICKENS(broilers)

Afteroraladministration,doxycyclineisrapidlyabsorbedreaching

maximumconcentrations(C

)around1.5h.Bioavailabilitywasabout

75%.Thepresenceoffoodinthegastrointestinaltractreducesits

absorption,reachingabioavailabilityaround60%andextending

considerablythetimeatwhichitreachesthemaximumpeak

concentration,(t

)3.3h.

PIGS

Afteranoraldoseof10mg/kg/day,theconcentrationatsteadystate

(Css)wasaround1.30µg/mLandplasmaeliminationhalf-life(t1/2)was

7.01h.

6. PHARMACEUTICALPARTICULARS

6.1.Listofexcipients

Pyrrolidone

Propyleneglycol

6.2.Incompatibilities

Donotmixwithotherveterinarymedicinalproducts.

6.3.Shelflife

Shelflifeoftheveterinarymedicinalproductaspackagedforsale:15

months

Shelflifeafterdilutionaccordingtodirections:24hours

Shelf-lifeafterfirstopeningtheimmediatepackaging:28days

Revised:May2013

AN:00844/2012

Page7of7

6.4.Specialprecautionsforstorage

Donotstoreabove25ºC.

Protectfromlight.

6.5.Natureandcompositionofimmediatepackaging

Theproductispackagedinwhitehigh-densitypolyethylenecontainersof

1Land5L.Containersareclosedwithascrewcapofthesamematerial

withinductionsealing.

6.6. Specialprecautionsforthedisposalofunusedveterinarymedicinal

productorwastematerialsderivedfromtheuseofsuchproducts

Anyunusedveterinarymedicinalproductorwastematerialsderivedfrom

suchveterinarymedicinalproductsshouldbedisposedofinaccordance

withlocalrequirements.

7. MARKETINGAUTHORISATIONHOLDER

LaboratoriosKarizoo,S.A.

PolígonoIndustrialLaBorda

MasPujades,11-12

08140 –CaldesdeMontbui(Barcelona)

SPAIN

8. MARKETINGAUTHORISATIONNUMBER

Vm31223/4000

9. DATEOFFIRSTAUTHORISATION

20August2008

10. DATEOFREVISIONOFTHETEXT

May2013

Approved: 23/05/2013

27-11-2018

INNUENDO: A cross‐sectoral platform for the integration of genomics in the surveillance of food‐borne pathogens

INNUENDO: A cross‐sectoral platform for the integration of genomics in the surveillance of food‐borne pathogens

Published on: Mon, 26 Nov 2018 Abstract In response to the EFSA call New approaches in identifying and characterizing microbial and chemical hazards, the project INNUENDO (https://sites.google.com/site/theinnuendoproject/) aimed to design an analytical platform and standard procedures for the use of whole‐genome sequencing in surveillance and outbreak investigation of food‐borne pathogens. The project firstly attempted to identify existing flaws and needs, and then to provide applicable cross‐sectorial ...

Europe - EFSA - European Food Safety Authority Publications

21-11-2018

Safety and efficacy of Monteban® G100 (narasin) for chickens for fattening

Safety and efficacy of Monteban® G100 (narasin) for chickens for fattening

Published on: Tue, 20 Nov 2018 The feed additive Monteban® G100, containing the active substance narasin, an ionophore anticoccidial, is intended to control coccidiosis in chickens for fattening at a dose of 60–70 mg/kg complete feed. Narasin is produced by fermentation. Limited data on the taxonomic identification of the production strain did not allow the proper identification of strain NRRL 8092 as Streptomyces aureofaciens. The FEEDAP Panel cannot conclude on the absence of genetic determinants for ...

Europe - EFSA - European Food Safety Authority Publications

20-10-2018

Scientific Opinion of Flavouring Group Evaluation 411 (FGE.411): 2‐(4‐methylphenoxy)‐N‐(1H‐pyrazol‐3‐yl)‐N‐(thiophen‐2‐ylmethyl)acetamide from chemical group 30 (miscellaneous substances)

Scientific Opinion of Flavouring Group Evaluation 411 (FGE.411): 2‐(4‐methylphenoxy)‐N‐(1H‐pyrazol‐3‐yl)‐N‐(thiophen‐2‐ylmethyl)acetamide from chemical group 30 (miscellaneous substances)

Published on: Fri, 19 Oct 2018 00:00:00 +0200 EFSA was requested to deliver a scientific opinion on the implications for human health of the flavouring substance 2‐(4‐methylphenoxy)‐N‐(1H‐pyrazol‐3‐yl)‐N‐(thiophen‐2‐ylmethyl)acetamide [FL‐no: 16.133], in the Flavouring Group Evaluation 411 (FGE.411), according to Regulation (EC) No 1331/2008 of the European Parliament and of the Council. The substance has not been reported to occur in natural source materials of botanical or animal origin. It is intende...

Europe - EFSA - European Food Safety Authority Publications

1-9-2018

Spodoptera frugiperda partial risk assessment

Spodoptera frugiperda partial risk assessment

Published on: Fri, 31 Aug 2018 00:00:00 +0200 EFSA was asked for a partial risk assessment of Spodoptera frugiperda for the territory of the EU focussing on the main pathways for entry, factors affecting establishment, risk reduction options and pest management. As a polyphagous pest, five commodity pathways were examined in detail. Aggregating across these and other pathways, we estimate that tens of thousands to over a million individual larvae could enter the EU annually on host commodities. Instigat...

Europe - EFSA - European Food Safety Authority Publications

29-8-2018

Safety assessment of the process ‘General Plastic’, based on Starlinger Decon technology, used to recycle post‐consumer PET into food contact materials

Safety assessment of the process ‘General Plastic’, based on Starlinger Decon technology, used to recycle post‐consumer PET into food contact materials

Published on: Fri, 10 Aug 2018 00:00:00 +0200 This scientific opinion of the EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids (CEF Panel) deals with the safety evaluation of the recycling process General Plastic (EU register No RECYC153), which is based on the Starlinger Decon technology. The decontamination efficiency of the process was demonstrated by a challenge test. The input of this process is hot caustic washed and dried poly(ethylene terephthalate) (PET) flakes orig...

Europe - EFSA - European Food Safety Authority Publications

29-8-2018

Protocol for the scientific opinion on the Tolerable Upper Intake Level of dietary sugars

Protocol for the scientific opinion on the Tolerable Upper Intake Level of dietary sugars

Published on: Fri, 10 Aug 2018 00:00:00 +0200 In June 2016, EFSA received a mandate from the national food competent authorities of five European countries (Denmark, Finland, Iceland, Norway and Sweden) to provide a dietary reference value (DRV) for sugars, with particular attention to added sugars. A draft protocol was developed with the aim of defining as much as possible beforehand the strategy that will be applied for collecting data, appraising the relevant evidence, and analysing and integrating t...

Europe - EFSA - European Food Safety Authority Publications

25-6-2018

FDA approves first drug comprised of an active ingredient derived from marijuana to treat rare, severe forms of epilepsy

FDA approves first drug comprised of an active ingredient derived from marijuana to treat rare, severe forms of epilepsy

FDA approved Epidiolex (cannabidiol) oral solution, the first drug comprised of an active ingredient derived from marijuana, to treat two rare and severe forms of epilepsy.

FDA - U.S. Food and Drug Administration

24-5-2018

FDA Approves Semintra, the First FDA-approved Animal Drug for the Control of Systemic Hypertension in Cats

FDA Approves Semintra, the First FDA-approved Animal Drug for the Control of Systemic Hypertension in Cats

The FDA has approved Semintra (telmisartan oral solution), the first FDA-approved animal drug to control systemic hypertension in cats. Semintra is an oral solution administered either directly into the cat’s mouth or on top of a small amount of food.

FDA - U.S. Food and Drug Administration

There are no news related to this product.